In two additional presentations, Gilead researchers presented data describing the unique structural and enzymological features of tenofovir that may help to explain the compound's favorable resistance profile.

In two additional presentations at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Gilead researchers presented data describing the unique structural and enzymological features of tenofovir that may help to explain the compound's favorable resistance profile.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.